HCM
HZNP

Highbridge Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Highbridge Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,500
Closed -$174K – 416
2023
Q3 		$174K Buy
+1,500
New +$161K 0.01% 189

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Highbridge Capital Management's HZNP Position: Q3 2023 in Review

Highbridge Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 20,000 shares — an estimated $2.15M sold.

Highbridge Capital Management first reported a position in HZNP in Q1 2015 and held it in 11 quarters. The position peaked at $35.8M in Q4 2015. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • Highbridge Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Highbridge Capital Management sold 20,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $2.15M.
  • Highbridge Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 11 quarters.
  • Highbridge Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $35.8M in Q4 2015.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Highbridge Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.